Integrating Emerging Evidence into the Management of Patients with Chronic Lymphocytic Leukemia (satellite symposium)

San Francisco, CA US
October 17, 2015

The goal of this activity is to improve the ability to optimize therapy and incorporate clinical advances into the management of patients with chronic lymphocytic leukemia.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other health care professionals who provide care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal treatment for patients with newly diagnosed chronic lymphocytic leukemia based on patient-specific and disease-specific factors
  • Choose optimal treatment for relapsed/refractory chronic lymphocytic leukemia in special patient populations
  • Explain how promising investigational agents may fit into the current treatment paradigm for chronic lymphocytic leukemia
Additional information

Jointly provided by NCCN and Clinical Care Options, LLC.

This activity is supported by educational grants from AbbVie Inc.; Genentech; and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Course summary
Available credit: 
  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician
Course opens: 
Course expires: 
Event starts: 
10/17/2015 - 6:45am EDT
Event ends: 
10/17/2015 - 7:45am EDT
San Francisco Marriott Marquis
780 Mission Street
Golden Gate A&B
San Francisco, CA 94103
United States

William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

Available Credit

  • 1.00 Participation
  • 1.00 Nurse
  • 1.00 Pharmacist
  • 1.00 Physician


Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing